NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

JANX

Janux Therapeutics Inc

Apr 25 • 04:00PM ET

31.05

Dollar change -1.02
Percentage change -3.18	%

Healthcare • Biotechnology • USA • NASD

Peers: BMRN BPMC KURA BLUE ALLO ADAP TVRD FATE PTCT AVIR

| Held by: VTI IWM XBI VXF IBB IWO SCHA VTWO VHT IDNA

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.28	Insider Own	16.42%	Shs Outstand	59.06M	Perf Week	4.58%
Market Cap	1.84B	Forward P/E	-	EPS next Y	-2.28	Insider Trans	7.84%	Shs Float	49.40M	Perf Month	3.09%
Income	-68.99M	PEG	-	EPS next Q	-0.36	Inst Own	107.87%	Short Float	18.91%	Perf Quarter	-29.61%
Sales	10.59M	P/S	173.30	EPS this Y	-41.41%	Inst Trans	51.20%	Short Ratio	10.33	Perf Half Y	-41.19%
Book/sh	17.32	P/B	1.79	EPS next Y	-26.06%	ROA	-9.57%	Short Interest	9.34M	Perf Year	-37.63%
Cash/sh	17.34	P/C	1.79	EPS next 5Y	-	ROE	-10.09%	52W Range	22.52 - 71.71	Perf YTD	-42.01%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-67.90%	ROI	-6.61%	52W High	-56.70%	Beta	3.21
Dividend TTM	-	Quick Ratio	59.21	Sales past 5Y	32.33%	Gross Margin	80.54%	52W Low	37.88%	ATR (14)	1.96
Dividend Ex-Date	-	Current Ratio	59.21	EPS Y/Y TTM	4.61%	Oper. Margin	-933.58%	RSI (14)	55.36	Volatility	5.35% 7.21%
Employees	81	Debt/Eq	0.02	Sales Y/Y TTM	30.99%	Profit Margin	-651.62%	Recom	1.15	Target Price	89.27
Option/Short	Yes / Yes	LT Debt/Eq	0.02	EPS Q/Q	-41.21%	Payout	-	Rel Volume	0.46	Prev Close	32.07
Sales Surprise	-99.85%	EPS Surprise	21.86%	Sales Q/Q	-100.00%	Earnings	Feb 27 AMC	Avg Volume	903.82K	Price	31.05
SMA20	9.91%	SMA50	1.20%	SMA200	-28.62%	Trades		Volume	418,711	Change	-3.18%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-03-24	Reiterated	H.C. Wainwright	Buy	$63 → $70
Dec-03-24	Reiterated	BTIG Research	Buy	$82 → $100
Nov-22-24	Initiated	Leerink Partners	Outperform	$79
Oct-24-24	Initiated	UBS	Buy	$69
Sep-06-24	Initiated	Stifel	Buy	$70
May-30-24	Initiated	Scotiabank	Sector Perform	$47
Mar-21-24	Initiated	BTIG Research	Buy	$62
Mar-20-24	Initiated	Cantor Fitzgerald	Overweight	$100
Apr-06-23	Initiated	Wedbush	Outperform	$24
Nov-14-22	Initiated	William Blair	Outperform

Apr-07-25 05:14PM	Janux Therapeutics: What's My Inflection Point? (Seeking Alpha) -5.39%
Apr-05-25 08:14AM	Janux Therapeutics: Buying For The Promising Pipeline, Holding For The Buyout (Seeking Alpha)
Mar-28-25 10:36AM	Is Janux Therapeutics Inc. (NASDAQ:JANX) the Best Up and Coming Stock to Buy According to Wall Street Analysts? (Insider Monkey)
Mar-26-25 09:40PM	Is Janux Therapeutics, Inc. (NASDAQ:JANX) the Best Small Cap Stock to Buy Before They Explode? (InsiderMonkey)
Mar-25-25 10:45AM	Janux Therapeutics, Inc. (JANX): Among Stocks Receiving the Most Insider Love in March (InsiderMonkey)
04:43PM	Loading…
Mar-20-25 04:43PM	Is Janux Therapeutics (JANX) a Worst High-Risk High-Reward Growth Stock to Buy? (InsiderMonkey)
09:05AM	Invesco Health Care Fund Q4 2024 Commentary (SeekingAlpha)
Mar-14-25 06:17PM	WEX, Lamb Weston, and More Stocks See Action From Activist Investors (Barrons.com)
12:15PM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
Mar-05-25 06:53PM	Janux Therapeutics, Inc. (JANX): Among The Stocks With At Least $30 Million In Insider Spending Recently (Insider Monkey) +5.04%
Mar-01-25 10:00AM	Janux Therapeutics price target lowered to $41 from $62 at Scotiabank (TipRanks)
Feb-27-25 04:01PM	Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights (Business Wire)
Feb-24-25 01:07PM	Janux Therapeutics, Inc. (JANX): Among the Oversold Biotech Stocks to Buy Now (Insider Monkey) -6.75%
Jan-24-25 04:01PM	Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer (Business Wire)
Dec-06-24 07:43PM	Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million (Business Wire) -5.14%
11:12PM	Loading…
Dec-04-24 11:12PM	Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants (Business Wire) +11.65%
06:23PM	Why Janux Therapeutics Crushed the Market Today (Motley Fool)
Dec-03-24 04:07PM	Janux Catapults 49% On 'Unprecedented' Results In Prostate Cancer; Vir Goes For A Ride (Investor's Business Daily) +48.98%
04:01PM	Janux Therapeutics Announces Proposed Public Offering (Business Wire)
11:58AM	Janux Rockets 41% in Five Days as Cancer Breakthrough Fuels Market Buzz (GuruFocus.com)
11:20AM	Janux Therapeutics Stock Soars on Prostate Cancer Drug Trial Results (Barrons.com)
10:01AM	Janux Skyrockets: 69% Surge This Morning Leads to 650% Gain in a Year (GuruFocus.com)
09:02AM	Janux, Vir Catapult On 'Unprecedented' Results In Prostate Cancer Patients (Investor's Business Daily)
06:13AM	Janux impresses Wall Street with new prostate cancer drug results (BioPharma Dive)
Dec-02-24 04:30PM	Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC (Business Wire) -11.13%
Nov-25-24 09:00AM	Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion Studies (Business Wire)
Nov-23-24 06:21AM	Janux Therapeutics initiated with an Outperform at Leerink (TipRanks)
Nov-15-24 08:34PM	Bitdeer Technologies, PBF Energy, and More Stocks See Action From Activist Investors (Barrons.com)
Nov-06-24 04:01PM	Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights (Business Wire)
Nov-01-24 06:33PM	Bath & Body Works, Paramount Global, and More Stocks See Action From Activist Investors (Barrons.com)
09:05PM	Loading…
Oct-23-24 09:05PM	Paradigm Biocapital Advisors LP Acquires Shares in Janux Therapeutics Inc (GuruFocus.com)
Oct-22-24 09:07PM	RA Capital Management Reduces Stake in Janux Therapeutics (GuruFocus.com)
Oct-07-24 05:08PM	Janux Therapeutics, Inc. (JANX): A Hot Stock to Buy Now (Insider Monkey)
Sep-26-24 07:30PM	Is Janux Therapeutics Inc. (JANX) the Best Performing Small-Cap Stock in 2024? (Insider Monkey)
Sep-20-24 06:39PM	Lennar, Bitdeer, and More Stocks See Action From Activist Investors (Barrons.com)
Sep-17-24 01:30AM	RA Capital Management L.P. Increases Stake in Janux Therapeutics Inc (GuruFocus.com)
Sep-14-24 07:33PM	Janux Therapeutics, Inc. (JANX): Among Hedge Funds Top Biotech Stock Picks (Insider Monkey)
Sep-13-24 06:10AM	Janux Therapeutics (JANX) Moves 6.5% Higher: Will This Strength Last? (Zacks) +7.48%
Aug-16-24 04:36PM	Southwest Airlines, Rocket Lab USA, and More Stocks See Action From Activist Investors (Barrons.com) +5.08%
Aug-07-24 11:54PM	JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace)
05:15PM	Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights (Business Wire)
Jul-22-24 04:01PM	Janux Therapeutics Announces Updates to Board of Directors (Business Wire) +6.80%
Jul-01-24 11:13AM	Google DeepMind CEO: 'This Is the Next $100 Billion AI Business' (InvestorPlace)
Jun-14-24 07:05PM	TruBridge, Evans Bancorp, and More Stocks See Action From Activist Investors (Barrons.com)
May-17-24 04:12PM	Google DeepMind CEO: 'This Is the Next $100 Billion AI Business' (InvestorPlace)
May-09-24 10:26AM	Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb (PR Newswire) -6.19%
May-08-24 09:06AM	Wedbush Raises Janux Therapeutics' PT to $74 From $53, Keeps Outperform Rating (MT Newswires) -9.97%
07:32AM	Janux Therapeutics Reports Narrower Q1 Loss, Misses Revenue Estimates (GuruFocus.com)
May-07-24 10:56PM	JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:01PM	Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights (Business Wire)
Apr-30-24 08:50AM	Here's What Could Help Janux Therapeutics (JANX) Maintain Its Recent Price Strength (Zacks)
Apr-25-24 11:28AM	11 Oversold MidCap Stocks To Buy Now (Insider Monkey)
Apr-17-24 01:12PM	Take the Money and Run: 3 Overbought Stocks to Sell ASAP (InvestorPlace) -5.12%
Apr-16-24 01:19PM	These 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come? (InvestorPlace)
Apr-15-24 12:54PM	Janux (JANX) Rises Almost 50% in a Week on Buyout Rumors (Zacks)
Apr-12-24 08:50AM	Janux Therapeutics (JANX) is on the Move, Here's Why the Trend Could be Sustainable (Zacks) +5.30%
05:40AM	Why Janux Therapeutics Stock Is Crushing It This Week (Motley Fool)
Apr-11-24 04:19PM	Biotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options (Investor's Business Daily) +12.06%
02:13PM	Why Is Cancer-Focused Janux Therapeutics Stock Trading Higher On Thursday? (Benzinga)
09:55AM	Wall Street Analysts Think Janux Therapeutics (JANX) Could Surge 40.3%: Read This Before Placing a Bet (Zacks)
09:17AM	Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options (Investor's Business Daily)
Apr-10-24 06:39PM	Why Janux Therapeutics Stock Soared as the Market Sagged Today (Motley Fool) +11.47%
Apr-08-24 09:35AM	After Plunging -11.78% in 4 Weeks, Here's Why the Trend Might Reverse for Janux Therapeutics (JANX) (Zacks) +9.99%
Mar-28-24 12:00PM	Janux Therapeutics (JANX) Upgraded to Buy: Here's What You Should Know (Zacks)
Mar-22-24 09:55AM	Wall Street Analysts Believe Janux Therapeutics (JANX) Could Rally 57.47%: Here's is How to Trade (Zacks)
Mar-20-24 03:44PM	Cancer-Focused Janux Therapeutics Platform Has 'Tremendous Opportunity': Analyst (Benzinga)
Mar-15-24 10:53AM	JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
09:45AM	2 Stocks That Have More Than Tripled This Year: Are They Buys? (Motley Fool)
Mar-08-24 04:31PM	Janux Therapeutics Inc (JANX) Reports Encouraging Clinical Data and Solid Financial Position ... (GuruFocus.com)
04:01PM	Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights (Business Wire)
Mar-02-24 06:56AM	After Soaring 222% in 1 Day, Is Janux Therapeutics Stock a Buy? (Motley Fool)
Mar-01-24 08:50AM	Recent Price Trend in Janux Therapeutics, Inc. (JANX) is Your Friend, Here's Why (Zacks)
Feb-29-24 01:22AM	Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants (Business Wire)
Feb-27-24 05:00PM	Janux Therapeutics Announces Proposed Public Offering of Common Stock (Business Wire) +229.47% -6.34%
04:04PM	Janux Stock Launches 230% On Its 'Significant Opportunity' In Prostate Cancer Treatment (Investor's Business Daily)
10:07AM	Janux Therapeutics Nearly Triples As Prostate Cancer Drug Shows 'Significant Opportunity' (Investor's Business Daily)
07:46AM	Why Is Janux Therapeutics (JANX) Stock Up 108% Today? (InvestorPlace)
07:15AM	Janux shares triple on early cancer immunotherapy data (BioPharma Dive)
Feb-26-24 04:05PM	Janux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors (Business Wire)
Feb-21-24 02:39AM	Janux Therapeutics, Inc. (JANX) Moves 5.6% Higher: Will This Strength Last? (Zacks) +31.93%
Feb-20-24 08:00AM	Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008 (Business Wire) +5.62%
Jan-08-24 09:00AM	Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific Officer (Business Wire)
Dec-01-23 09:55AM	Does Janux Therapeutics, Inc. (JANX) Have the Potential to Rally 205.5% as Wall Street Analysts Expect? (Zacks)
Nov-15-23 09:55AM	Wall Street Analysts See a 220.17% Upside in Janux Therapeutics, Inc. (JANX): Can the Stock Really Move This High? (Zacks) +5.40%
Nov-10-23 09:35AM	Janux Therapeutics, Inc. (JANX) Loses -34.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Nov-07-23 04:01PM	Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights (Business Wire)
Aug-17-23 09:56AM	10 Healthcare Stocks with Insider Buying (Insider Monkey)
Aug-10-23 09:55AM	Wall Street Analysts Think Janux Therapeutics, Inc. (JANX) Could Surge 120.82%: Read This Before Placing a Bet (Zacks)
Aug-08-23 05:40PM	Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +6.82%
04:01PM	Janux Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights (Business Wire)
Jul-20-23 12:00PM	All You Need to Know About Janux Therapeutics, Inc. (JANX) Rating Upgrade to Buy (Zacks)
09:55AM	Wall Street Analysts Believe Janux Therapeutics, Inc. (JANX) Could Rally 120.65%: Here's is How to Trade (Zacks)
06:40AM	Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Could Be 28% Below Their Intrinsic Value Estimate (Simply Wall St.)
Jul-17-23 08:45AM	Janux Therapeutics Announces Pricing of $60 Million Underwritten Offering of Common Stock and Pre-Funded Warrants (Business Wire)
08:00AM	Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1a Dose Escalation for PSMA-TRACTr JANX007 and an Update on Pipeline Programs (Business Wire)
Jun-05-23 04:35PM	Janux Therapeutics Appoints Zachariah McIver, D.O., Ph.D., Vice President, Clinical Development (Business Wire)
10:38AM	Shareholders have faith in loss-making Janux Therapeutics (NASDAQ:JANX) as stock climbs 20% in past week, taking one-year gain to 29% (Simply Wall St.)
May-09-23 05:15PM	Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Janux Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights (Business Wire)

Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded by David Campbell in June 2017 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Meyer Andrew Hollman	Chief Business Officer	Apr 21 '25	Option Exercise	4.21	3,334	14,036	85,473	Apr 23 08:00 PM
Meyer Andrew Hollman	Chief Business Officer	Apr 21 '25	Sale	30.00	3,334	100,020	82,139	Apr 23 08:00 PM
ANDREW MEYER	Officer	Apr 21 '25	Proposed Sale	29.69	3,334	98,986		Apr 21 04:18 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Mar 06 '25	Buy	30.78	372,093	11,453,023	10,031,081	Mar 07 06:05 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Mar 05 '25	Buy	30.64	341,742	10,471,352	9,658,988	Mar 07 06:05 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Mar 07 '25	Buy	31.02	110,206	3,418,590	10,141,287	Mar 07 06:05 PM
Meyer Andrew Hollman	Chief Business Officer	Mar 03 '25	Option Exercise	4.21	3,334	14,036	85,473	Mar 05 08:00 PM
Meyer Andrew Hollman	Chief Business Officer	Mar 03 '25	Sale	32.15	3,334	107,174	82,139	Mar 05 08:00 PM
ANDREW MEYER	Officer	Mar 03 '25	Proposed Sale	32.89	3,334	109,655		Mar 03 04:25 PM
Meyer Andrew Hollman	Chief Business Officer	Feb 03 '25	Option Exercise	4.21	3,334	14,036	85,473	Feb 05 08:00 PM
Meyer Andrew Hollman	Chief Business Officer	Feb 03 '25	Sale	42.29	3,334	140,999	82,139	Feb 05 08:00 PM
ANDREW MEYER	Officer	Feb 03 '25	Proposed Sale	43.48	3,334	144,962		Feb 03 04:18 PM
Campbell David Alan	President and CEO	Jan 07 '25	Sale	60.00	5,000	300,004	293,054	Jan 08 08:00 PM
Campbell David Alan	Officer	Jan 07 '25	Proposed Sale	60.00	5,000	300,004		Jan 07 04:11 PM
Meyer Andrew Hollman	Chief Business Officer	Jan 02 '25	Sale	54.88	13,334	731,785	82,139	Jan 03 05:10 PM
ANDREW MEYER	Officer	Jan 02 '25	Proposed Sale	53.54	13,334	713,902		Jan 02 04:24 PM
Campbell David Alan	President and CEO	Dec 24 '24	Sale	56.19	25,000	1,404,805	217,054	Dec 27 08:00 PM
Campbell David Alan	Officer	Dec 26 '24	Proposed Sale	56.19	25,000	1,404,805		Dec 26 10:00 AM
Meyer Andrew Hollman	Chief Business Officer	Dec 19 '24	Option Exercise	20.24	9,881	199,985	77,473	Dec 20 06:25 PM
Campbell David Alan	President and CEO	Dec 03 '24	Sale	67.00	15,000	1,005,000	242,054	Dec 03 08:00 PM
Campbell David Alan	President and CEO	Nov 25 '24	Sale	51.60	25,000	1,289,879	257,054	Nov 27 08:00 PM
Reardon Tighe	FORMER OFFICER	Nov 01 '24	Proposed Sale	53.44	5,202	277,987		Nov 01 05:05 PM
Lichter Jay	FORMER DIRECTOR	Nov 01 '24	Proposed Sale	53.31	1,139	60,723		Nov 01 05:02 PM
Avalon Ventures XI, L.P.	10% Owner	Nov 01 '24	Proposed Sale	53.66	56,440	3,028,665		Nov 01 04:30 PM
Avalon BioVentures SPV I, L.P.	10% Owner	Nov 01 '24	Proposed Sale	53.66	57,627	3,092,362		Nov 01 04:24 PM
Avalon BioVentures I, LP	10% Owner	Nov 01 '24	Proposed Sale	53.66	10,934	586,731		Nov 01 04:17 PM
Reardon Tighe	Former officer	Nov 01 '24	Proposed Sale	52.99	2,999	158,910		Nov 01 04:07 PM
Campbell David Alan	President and CEO	Oct 28 '24	Sale	53.54	25,000	1,338,559	282,054	Oct 30 07:30 PM
Reardon Tighe	FORMER OFFICER	Oct 28 '24	Proposed Sale	53.41	15,122	807,666		Oct 28 05:07 PM
Lichter Jay	FORMER DIRECTOR	Oct 28 '24	Proposed Sale	53.51	3,419	182,954		Oct 28 05:01 PM
Reardon Tighe	Former officer	Oct 28 '24	Proposed Sale	53.36	9,061	483,520		Oct 28 04:46 PM
Avalon Ventures XI, L.P.	10% Owner	Oct 25 '24	Proposed Sale	53.33	169,320	9,029,544		Oct 25 04:57 PM
Avalon BioVentures I, LP	10% Owner	Oct 25 '24	Proposed Sale	53.33	32,800	1,749,162		Oct 25 04:51 PM
Avalon BioVentures SPV I, L.P.	10% Owner	Oct 25 '24	Proposed Sale	53.33	172,880	9,219,392		Oct 25 04:44 PM
Lichter Jay	FORMER DIRECTOR	Oct 24 '24	Proposed Sale	53.37	4,921	262,653		Oct 24 05:53 PM
Reardon Tighe	FORMER OFFICER	Oct 24 '24	Proposed Sale	5.28	217,690	1,148,928		Oct 24 05:04 PM
Lichter Jay	10% Owner	Sep 13 '24	Option Exercise	17.29	3,815	65,951	10,815	Oct 24 04:15 PM
Lichter Jay	10% Owner	Sep 13 '24	Sale	46.68	3,815	178,084	7,000	Oct 24 04:15 PM
Avalon BioVentures SPV I, L.P.	10% Owner	Oct 23 '24	Proposed Sale	51.23	248,797	12,745,011		Oct 23 05:59 PM
Avalon BioVentures I, LP	10% Owner	Oct 23 '24	Proposed Sale	51.23	47,203	2,418,041		Oct 23 05:38 PM
Avalon Ventures XI, L.P.	10% Owner	Oct 23 '24	Proposed Sale	51.23	243,672	12,482,475		Oct 23 05:07 PM
Reardon Tighe	Former officer	Oct 23 '24	Proposed Sale	51.01	13,039	665,094		Oct 23 04:36 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Oct 18 '24	Buy	44.75	1,200,000	53,700,000	9,317,246	Oct 22 04:20 PM
Reardon Tighe	FORMER OFFICER	Oct 21 '24	Proposed Sale	49.43	10,769	532,310		Oct 21 04:43 PM
Reardon Tighe	Former officer	Oct 21 '24	Proposed Sale	50.21	6,324	317,544		Oct 21 04:25 PM
Lichter Jay	FORMER DIRECTOR	Oct 21 '24	Proposed Sale	49.49	2,434	120,454		Oct 21 01:39 PM
Avalon Ventures XI, L.P.	10% Owner	Oct 16 '24	Option Exercise	18.07	10,515	190,031	17,402	Oct 18 06:51 PM
Avalon Ventures XI, L.P.	10% Owner	Oct 17 '24	Option Exercise	18.08	1,769	31,979	8,214	Oct 18 06:51 PM
Avalon Ventures XI, L.P.	10% Owner	Oct 18 '24	Sale	45.76	801,751	36,691,728	401,321	Oct 18 06:51 PM
Avalon Ventures XI, L.P.	10% Owner	Oct 18 '24	Sale	45.76	660,018	30,205,389	2,071,799	Oct 18 06:51 PM
Avalon Ventures XI, L.P.	10% Owner	Oct 16 '24	Sale	49.99	108,906	5,444,479	529,173	Oct 18 06:51 PM
Avalon Ventures XI, L.P.	10% Owner	Oct 16 '24	Sale	50.08	100,610	5,038,589	6,445	Oct 18 06:51 PM
Avalon Ventures XI, L.P.	10% Owner	Oct 17 '24	Sale	50.02	1,843	92,187	6,371	Oct 18 06:51 PM
Avalon Ventures XI, L.P.	10% Owner	Oct 18 '24	Proposed Sale	50.38	118,194	5,954,737		Oct 18 04:57 PM
Avalon BioVentures I, LP	10% Owner	Oct 18 '24	Proposed Sale	50.38	22,895	1,153,468		Oct 18 04:48 PM
Avalon BioVentures SPV I, L.P.	10% Owner	Oct 18 '24	Proposed Sale	50.38	120,680	6,079,984		Oct 18 04:39 PM
Reardon Tighe	FORMER OFFICER	Oct 17 '24	Proposed Sale	50.01	8,158	408,020		Oct 17 05:06 PM
Lichter Jay	FORMER DIRECTOR	Oct 17 '24	Proposed Sale	50.05	1,842	92,193		Oct 17 04:24 PM
Reardon Tighe	Former officer	Oct 17 '24	Proposed Sale	49.67	4,784	237,606		Oct 17 04:18 PM
Reardon Tighe	FORMER OFFICER	Oct 16 '24	Proposed Sale	50.78	48,462	2,460,829		Oct 16 06:14 PM
Avalon BioVentures I, LP	10% Owner	Oct 16 '24	Proposed Sale	49.96	17,367	867,595		Oct 16 05:35 PM
Lichter Jay	FORMER DIRECTOR	Oct 16 '24	Proposed Sale	50.80	10,957	556,599		Oct 16 05:28 PM
Avalon BioVentures SPV I, L.P.	10% Owner	Oct 16 '24	Proposed Sale	49.96	91,539	4,572,999		Oct 16 05:25 PM
Avalon Ventures XI, L.P.	10% Owner	Oct 16 '24	Proposed Sale	49.96	89,653	4,478,780		Oct 16 05:17 PM
Reardon Tighe	Former officer	Oct 16 '24	Proposed Sale	51.34	28,993	1,488,403		Oct 16 05:10 PM
Avalon Ventures XI, L.P.	10% Owner	Sep 27 '24	Option Exercise	18.07	1,752	31,652	8,752	Sep 30 08:49 PM
Avalon Ventures XI, L.P.	10% Owner	Sep 30 '24	Option Exercise	18.07	919	16,608	7,845	Sep 30 08:49 PM
Avalon Ventures XI, L.P.	10% Owner	Sep 26 '24	Sale	47.23	109,700	5,180,839	555,727	Sep 30 08:49 PM
Avalon Ventures XI, L.P.	10% Owner	Sep 26 '24	Sale	47.23	90,300	4,264,629	2,868,875	Sep 30 08:49 PM
Avalon Ventures XI, L.P.	10% Owner	Sep 27 '24	Sale	46.46	57,590	2,675,750	546,540	Sep 30 08:49 PM
Avalon Ventures XI, L.P.	10% Owner	Sep 27 '24	Sale	46.45	49,231	2,286,878	6,926	Sep 30 08:49 PM
Avalon Ventures XI, L.P.	10% Owner	Sep 30 '24	Sale	46.24	958	44,298	6,887	Sep 30 08:49 PM
Lichter Jay	FORMER DIRECTOR	Sep 30 '24	Proposed Sale	46.24	958	44,302		Sep 30 05:34 PM
Reardon Tighe	FORMER OFFICER	Sep 30 '24	Proposed Sale	46.61	4,493	209,407		Sep 30 05:29 PM
Reardon Tighe	Former Officer	Sep 30 '24	Proposed Sale	46.04	2,537	116,803		Sep 30 04:08 PM
Meyer Andrew Hollman	Chief Business Officer	Sep 27 '24	Option Exercise	4.21	50,000	210,500	117,592	Sep 27 07:32 PM
Meyer Andrew Hollman	Chief Business Officer	Sep 27 '24	Sale	45.96	50,000	2,297,755	67,592	Sep 27 07:32 PM
DiRaimondo Thomas	Chief Scientific Officer	Sep 27 '24	Sale	46.34	5,000	231,716	97,938	Sep 27 07:31 PM
Campbell David Alan	President and CEO	Sep 27 '24	Sale	46.31	25,000	1,157,641	307,054	Sep 27 07:30 PM
Reardon Tighe	FORMER OFFICER	Sep 27 '24	Proposed Sale	45.92	7,812	358,755		Sep 27 06:31 PM
Avalon BioVentures SPV I, L.P.	10% Owner	Sep 27 '24	Proposed Sale	46.43	48,403	2,247,248		Sep 27 05:05 PM
Lichter Jay	FORMER DIRECTOR	Sep 27 '24	Proposed Sale	46.19	1,826	84,335		Sep 27 04:54 PM
Avalon BioVentures I, LP	10% Owner	Sep 27 '24	Proposed Sale	46.43	9,187	426,527		Sep 27 04:51 PM
Avalon Ventures XI, L.P.	10% Owner	Sep 27 '24	Proposed Sale	46.43	47,405	2,200,913		Sep 27 04:51 PM
THOMAS DIRAIMONDO	Officer	Sep 27 '24	Proposed Sale	46.62	5,000	233,100		Sep 27 04:24 PM
Reardon Tighe	Former officer	Sep 27 '24	Proposed Sale	46.18	4,832	223,158		Sep 27 04:18 PM
Campbell David Alan	Officer	Sep 27 '24	Proposed Sale	48.33	90,000	4,350,000		Sep 27 04:05 PM
ANDY MEYER	Officer	Sep 27 '24	Proposed Sale	45.96	50,000	2,297,755		Sep 27 04:01 PM
Avalon Ventures XI, L.P.	10% Owner	Sep 26 '24	Proposed Sale	47.19	90,300	4,260,861		Sep 26 05:57 PM
Avalon BioVentures SPV I, L.P.	10% Owner	Sep 26 '24	Proposed Sale	47.19	92,200	4,350,513		Sep 26 05:35 PM
Avalon BioVentures I, LP	10% Owner	Sep 26 '24	Proposed Sale	47.19	17,500	825,743		Sep 26 05:13 PM
Lichter Jay	FORMER DIRECTOR	Sep 13 '24	Proposed Sale	46.68	3,815	178,084		Sep 13 05:01 PM
Avalon BioVentures I, LP	10% Owner	Sep 12 '24	Proposed Sale	47.00	30,613	1,438,811		Sep 12 09:18 PM
Avalon BioVentures SPV I, L.P.	10% Owner	Sep 12 '24	Proposed Sale	47.00	161,356	7,583,732		Sep 12 09:07 PM
Avalon Ventures XI, L.P.	10% Owner	Sep 12 '24	Proposed Sale	47.00	158,031	7,427,757		Sep 12 08:54 PM
Avalon Ventures XI, L.P.	10% Owner	Sep 12 '24	Sale	47.00	191,969	9,022,543	573,227	Sep 12 08:42 PM
Avalon Ventures XI, L.P.	10% Owner	Sep 12 '24	Sale	47.00	158,031	7,427,457	2,959,175	Sep 12 08:42 PM
Avalon Ventures XI, L.P.	10% Owner	Sep 10 '24	Sale	46.53	55,446	2,579,823	603,840	Sep 12 08:42 PM
Avalon Ventures XI, L.P.	10% Owner	Sep 10 '24	Sale	46.53	45,645	2,123,797	3,117,206	Sep 12 08:42 PM
Reardon Tighe	FORMER OFFICER	Sep 12 '24	Proposed Sale	47.42	15,223	721,932		Sep 12 06:23 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

JANX

Janux Therapeutics Inc

Upgrade your FINVIZ experience